OpenLB
Open Library of Bioscience
Advanced Search
Expert review of clinical pharmacology
May, 2015;8 (3): 321-34.

Pharmacologic and clinical evaluation of posaconazole.

Jason N Moore, Jason R Healy, Walter K Kraft
Author Information
  1. Jason N Moore: Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 132 South Tenth Street, Main Building, Room 1170, Philadelphia, PA 19107, USA.
PMID: 25916666 DOI: 10.1586/17512433.2015.1034689

Abstract

Posaconazole, a broad-spectrum triazole antifungal agent, is approved for the prevention of invasive aspergillosis and candidiasis in addition to the treatment of oropharyngeal candidiasis. There is evidence of efficacy in the treatment and prevention of rarer, more difficult-to-treat fungal infections. Posaconazole oral suspension solution has shown limitations with respect to fasting state absorption, elevated gastrointestinal pH and increased motility. The newly approved delayed-release oral tablet and intravenous solution formulations provide an attractive treatment option by reducing interpatient variability and providing flexibility in critically ill patients. On the basis of clinical experience and further clinical studies, posaconazole was found to be a valuable pharmaceutical agent for the treatment of life-threatening fungal infections. This review will examine the development history of posaconazole and highlight the most recent advances.

Keywords

antifungal immunosuppression invasive fungal infection pharmacokinetics pharmacology posaconazole triazole

References

  1. N Engl J Med. 2007 Jan 25;356(4):335-47 [PMID: 17251530]
  2. J Antimicrob Chemother. 2008 Jan;61 Suppl 1:i35-40 [PMID: 18063603]
  3. Antimicrob Agents Chemother. 2005 Sep;49(9):3640-5 [PMID: 16127033]
  4. Eur J Clin Microbiol Infect Dis. 2014 Apr;33(4):629-38 [PMID: 24173819]
  5. Clin Infect Dis. 2011 Feb 15;52(4):e56-93 [PMID: 21258094]
  6. N Engl J Med. 2004 Feb 26;350(9):950-2 [PMID: 14985500]
  7. Clin Pharmacokinet. 2011 Nov 1;50(11):725-34 [PMID: 21973269]
  8. Antimicrob Agents Chemother. 2006 Jun;50(6):1993-9 [PMID: 16723557]
  9. Antimicrob Agents Chemother. 2012 Nov;56(11):5503-10 [PMID: 22890761]
  10. Antimicrob Agents Chemother. 2011 Mar;55(3):1308-11 [PMID: 21189337]
  11. Clin Infect Dis. 2008 Feb 1;46(3):327-60 [PMID: 18177225]
  12. Clin Infect Dis. 2006 Jul 1;43(1):25-31 [PMID: 16758414]
  13. Chest. 2007 Sep;132(3):952-8 [PMID: 17573510]
  14. Bone Marrow Transplant. 2010 May;45(5):925-32 [PMID: 19802030]
  15. Clin Infect Dis. 2010 Feb 1;50(3):291-322 [PMID: 20047480]
  16. Pediatr Infect Dis J. 2011 Sep;30(9):794-7 [PMID: 21772229]
  17. Mycopathologia. 2014 Oct;178(3-4):259-65 [PMID: 25103141]
  18. Pharmacoeconomics. 2011 Mar;29(3):251-68 [PMID: 21309616]
  19. Antimicrob Agents Chemother. 2014 Oct;58(10):5758-65 [PMID: 25049247]
  20. Mycoses. 2014 Feb;57(2):90-7 [PMID: 23790060]
  21. Can J Infect Dis Med Microbiol. 2012 Summer;23(2):e44-7 [PMID: 23730320]
  22. Antimicrob Agents Chemother. 2009 Mar;53(3):958-66 [PMID: 19075045]
  23. Future Microbiol. 2007 Jun;2(3):245-56 [PMID: 17661697]
  24. J Antimicrob Chemother. 2005 Oct;56(4):745-55 [PMID: 16135526]
  25. Clin Infect Dis. 2014 May;58(9):1308-11 [PMID: 24585567]
  26. Intern Med J. 2014 Dec;44(12b):1364-88 [PMID: 25482746]
  27. Br J Clin Pharmacol. 2010 Oct;70(4):471-80 [PMID: 20840439]
  28. Pharmacotherapy. 2007 Jun;27(6):825-34 [PMID: 17542765]
  29. Clin Infect Dis. 2014 Jul 15;59(2):e10-52 [PMID: 24973422]
  30. Clin Infect Dis. 2007 Feb 15;44(4):607-14 [PMID: 17243069]
  31. Antimicrob Agents Chemother. 2009 Nov;53(11):4749-52 [PMID: 19738015]
  32. Int J Antimicrob Agents. 2012 Jun;39(6):510-3 [PMID: 22481057]
  33. J Antimicrob Chemother. 2010 May;65(5):1052-61 [PMID: 20237074]
  34. Clin Pharmacokinet. 2010 Jun;49(6):379-96 [PMID: 20481649]
  35. Antimicrob Agents Chemother. 2014 Jul;58(7):3610-7 [PMID: 24733463]
  36. J Infect. 2007 Apr;54(4):319-27 [PMID: 16824608]
  37. Antimicrob Agents Chemother. 2012 Aug;56(8):4196-201 [PMID: 22615291]
  38. Expert Opin Drug Saf. 2013 Mar;12(2):265-74 [PMID: 23360443]
  39. Antimicrob Agents Chemother. 2013 Dec;57(12):6081-4 [PMID: 24060872]
  40. Clin Infect Dis. 2007 Sep 1;45(5):562-8 [PMID: 17682989]
  41. Antimicrob Agents Chemother. 2014 Nov;58(11):6993-5 [PMID: 25199774]
  42. Antimicrob Agents Chemother. 2014 Jul;58(7):4020-5 [PMID: 24798274]
  43. Antimicrob Agents Chemother. 2003 Sep;47(9):2788-95 [PMID: 12936975]
  44. N Engl J Med. 2014 May 15;370(20):1899-908 [PMID: 24827034]
  45. J Chromatogr A. 2003 Feb 14;987(1-2):243-8 [PMID: 12613818]
  46. Clin Infect Dis. 2007 Dec 15;45(12):1610-7 [PMID: 18190324]
  47. Drug Healthc Patient Saf. 2010;2:27-38 [PMID: 21701616]
  48. Antimicrob Agents Chemother. 2010 Feb;54(2):860-5 [PMID: 19917751]
  49. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238 [PMID: 19747629]
  50. Med Mycol. 2009;47 Suppl 1:S349-54 [PMID: 18663660]
  51. Clin Pharmacol Ther. 2010 Jul;88(1):115-9 [PMID: 20505665]
  52. Br J Dermatol. 2012 Feb;166(2):389-98 [PMID: 21967490]
  53. Clin Microbiol Infect. 2012 Dec;18 Suppl 7:38-52 [PMID: 23137136]
  54. J Clin Pharm Ther. 2009 Jun;34(3):301-11 [PMID: 19646076]
  55. Int J Antimicrob Agents. 2014 Aug;44(2):140-4 [PMID: 25059446]
  56. Antimicrob Agents Chemother. 2004 Sep;48(9):3543-51 [PMID: 15328123]
  57. N Engl J Med. 2007 Jan 25;356(4):348-59 [PMID: 17251531]
  58. Lancet Infect Dis. 2005 Dec;5(12):775-85 [PMID: 16310149]
  59. Clin Pharmacokinet. 2005;44(2):211-20 [PMID: 15656699]
  60. Antimicrob Agents Chemother. 2015 Feb;59(2):1246-51 [PMID: 25512407]
  61. Clin Infect Dis. 2006 Apr 1;42(7):e61-5 [PMID: 16511748]
  62. Clin Infect Dis. 2009 Mar 1;48(5):503-35 [PMID: 19191635]
  63. Int J Antimicrob Agents. 2011 Mar;37(3):266-9 [PMID: 21236645]
  64. J Antimicrob Chemother. 2012 Nov;67(11):2725-30 [PMID: 22833639]

Grants

  1. T32 GM008562/NIGMS NIH HHS
  2. T32GM008562/NIGMS NIH HHS

MeSH Term

Animals
Antifungal Agents
Aspergillosis
Candidiasis
Chemistry, Pharmaceutical
Critical Illness
Delayed-Action Preparations
Humans
Mycoses
Triazoles

Chemicals

Antifungal Agents
Delayed-Action Preparations
Triazoles
posaconazole
Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review
Article has an altmetric score of 3

Word Cloud

Created with Highcharts 10.0.0treatmentposaconazolefungalclinicalPosaconazoletriazoleantifungalagentapprovedpreventioninvasivecandidiasisinfectionsoralsolutionbroad-spectrumaspergillosisadditionoropharyngealevidenceefficacyrarerdifficult-to-treatsuspensionshownlimitationsrespectfastingstateabsorptionelevatedgastrointestinalpHincreasedmotilitynewlydelayed-releasetabletintravenousformulationsprovideattractiveoptionreducinginterpatientvariabilityprovidingflexibilitycriticallyillpatientsbasisexperiencestudiesfoundvaluablepharmaceuticallife-threateningreviewwillexaminedevelopmenthistoryhighlightrecentadvancesPharmacologicevaluationimmunosuppressioninfectionpharmacokineticspharmacology

Similar Articles

Cited By